基于肠道微生态探讨黄连素在代谢性疾病中的抗炎作用

肠道菌群与能量代谢密切相关,其组成和代谢紊乱可通过多种途径导致胰岛素抵抗,肥胖和2型糖尿病。黄连素因具有减重、降糖、调脂等作用被广泛用于肥胖、2型糖尿病及非酒精性脂肪性肝病等代谢性疾病的辅助治疗；研究表明,黄连素可调节肠道菌群的组成和代谢,改善肠道微生态环境,从而改善胰岛素抵抗和代谢。本文综述了黄连素通过肠道菌群-炎症轴在干预代谢性疾病的研究进展,以期为代谢性疾病的治疗寻找新的策略,并为今后该领域的深入研究提供指导意义。

Anti-inflammatory Activities of Berberine in the Treatment of Metabolic Disorders by Regulating the Gut Microbiota*

The gut microbiota is closely related to the energy metabolism, and the disorder of its composition and metabolism can lead to insulin resistance, obesity and type 2 diabetes (T2DM) through multiple pathways. Berberine is used as an adjuvant treatment for metabolic diseases, such as obesity, T2DM, and nonalcoholic fatty liver disease, due to its effects on weight loss, hypoglycemia, lipid regulation, and other physiological parameters. Recent studies have shown that berberine can regulate the composition and metabolism of the gut microbiota, improve the gut micro-ecological environment, thereby ameliorating insulin resistance and metabolism. This review clarifies how the gut microbiota induces systemic low-grade inflammation and the development of metabolic diseases. It also explores berberine intervention in metabolic diseases, affecting the intestinal microbiota-inflammation axis, in order to find new therapeutic strategies for the treatment of such diseases and to provide important guidance for in-depth research in this field.